What biomarker tests are recommended for Lymphoma

Biomarker Testing for Lymphoma: What You Should Know

Biomarker testing is an important part of understanding your lymphoma and determining the best treatment approach. Let me explain what tests are typically recommended and why they matter.

What Are Biomarkers?

Biomarkers are specific proteins or genetic changes found in cancer cells that help doctors understand your lymphoma better. Think of them as "fingerprints" that identify what type of lymphoma you have and how it might respond to treatment.

Key Biomarker Tests for Lymphoma

According to NCCN Guidelines for Patients, here are the main types of biomarker testing:

1. Immunophenotyping

This test uses antibodies (special proteins) to detect specific markers on the surface of lymphoma cells. For example, in follicular lymphoma, doctors typically look for patterns like:

• CD10+, BCL2+, CD20+, and BCL6+
• CD23+/- (may or may not be present)
• CD5-, CD43- (should be absent)

These marker patterns help distinguish your specific type of lymphoma from others, which is crucial for choosing the right treatment.

2. Mutation Testing

Your lymphoma cells may have specific genetic changes (mutations) that can be targeted with certain therapies. According to NCCN Guidelines, mutation testing looks for:

• Deletions (missing pieces of genes)
• Amplifications (duplicated genes)
• Translocations (genes switched between chromosomes)
• Point mutations (single changes in genes)

Some mutations can develop or change during treatment, so your doctor may recommend repeat testing if your lymphoma isn't responding as expected.

3. Flow Cytometry

This laboratory method identifies and counts specific cells by using light-sensitive dyes. It helps detect markers on cells from your blood, bone marrow, or biopsy samples—particularly useful for identifying immune system markers that define your lymphoma type.

4. Molecular Residual Disease (MRD) Testing

This newer test detects remaining cancer cells after treatment by looking for circulating tumor DNA (ctDNA) in your blood. According to recent NCCN Guidelines for B-Cell Lymphomas, MRD testing can:

• Identify molecular recurrence before symptoms appear
• Help guide whether additional treatment is needed
• Detect relapse approximately 6-7 months earlier than imaging scans

Why These Tests Matter

Different lymphoma subtypes (like marginal zone lymphoma, follicular lymphoma, or diffuse large B-cell lymphoma) have different biomarker patterns. Understanding your specific biomarkers helps your oncology team:

• Confirm your exact lymphoma diagnosis
• Predict how your cancer might behave
• Select targeted therapies that work best for your specific mutations
• Monitor for treatment resistance
• Detect early signs of recurrence

Questions to Ask Your Care Team

1. Which biomarker tests have been done on my lymphoma sample?
2. What specific mutations or markers were found, and what do they mean for my treatment options?
3. Are there any targeted therapies available based on my biomarkers?
4. Will you recommend MRD testing after my treatment to monitor for recurrence?
5. If my lymphoma doesn't respond to initial treatment, will you repeat biomarker testing to check for new mutations?

Important Note

The specific biomarkers tested and their clinical significance depend on your particular lymphoma subtype. Your oncology team will determine which tests are most relevant for your situation based on your diagnosis and treatment plan.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.